Comparison of the predictive value of area under the curve versus maximum serum concentration of intravenous tobramycin in cystic fibrosis patients treated for an acute pulmonary exacerbation.
antibiotic therapy
cystic fibrosis
pharmacodynamics
pharmacokinetics
tobramycin
Journal
Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
19
04
2021
received:
03
01
2021
accepted:
21
06
2021
pubmed:
10
7
2021
medline:
15
12
2021
entrez:
9
7
2021
Statut:
ppublish
Résumé
The primary objective of this study was to compare the therapeutic predictive value of area under the curve (AUC A retrospective review was conducted in patients aged at least 1 month with a diagnosis of CF receiving IV tobramycin for treatment of a PsA APE and admitted to the University of Kentucky between August 2015 and August 2019. Patients were excluded if they had no growth of PsA on sputum culture or if two postdose tobramycin levels were not obtained following a dose adjustment of ≥20%. A total of 44 pediatric and 107 adult patient encounters met inclusion criteria. In patients with therapeutic success (n = 91), 75.8% had an AUC The results of this study indicate that both AUC
Substances chimiques
Anti-Bacterial Agents
0
Tobramycin
VZ8RRZ51VK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3209-3216Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Bhagirath A, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC pulmonary medicine. 2016;16(1):174.
Kerem E, Viviani L, Zolin A, et al, ECFS Patient Registry Steering Group. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry. Eur Respir J. 2014;43(1):125-133.
Flume PA, Mogayzel PJ, Robinson KA, et al, Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-808.
Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet. 1995;28(2):143-160.
Kelvin H, Tan V, Mulheran M, Knox AJ, Smyth AR. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med. 2003;167:819-823.
Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis-caution with trough concentrations. J Cyst Fibros. 2007;6(2):125-130.
Barclay ML, Kirkpatrick CM, Begg EJ. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet. 1999;36(2):89-98.
Bates RD, Nahata MC, Jones JW, et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest. 1997;112(5):1208-1213.
ZEMDRI® (plazomicin) injection package insert. Achaogen Inc. Revised 1/2020.
University of Kentucky Department of Pharmacy. 2020. University of Kentucky Blue Book: Therapeutic Drug Monitoring. : Retrieved from http://careweb/ICISdocs/Aminoglycoside%20Blue%20Book_061720.pdf
Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43(7):1549-1555.
Prescott WA, Nagel JL. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis. Pharmacotherapy. 2010;30(1):95-108.
Khwaja A. Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for acute kidney injury. Nephron Clin Pract. 2012;120:179-184.
Zaske DE. Aminoglycosides. In: Evans WE, Schentag JJ, Jusko WJ, Relling MV editors., Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics, Inc; 1992:14-1-1442.
VandenBussche HL, Homnick DN. Evaluation of serum concentrations achieved with an empiric once-daily tobramycin dosage regimen in children and adults with cystic fibrosis. J Pediatr Pharmacol Ther. 2012;17(1):67-77.
Young DC, Zobell JT, Stockmann C, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatr Pulmonol. 2013;48(11):1047-1061.
Zobell JT, Epps K, Kittell F, et al. Tobramycin and Beta-Lactam antibiotic use in cystic fibrosis exacerbations: a pharmacist approach. J Pediatr Pharmacol Ther. 2016;21(3):239-246.
Smyth AR, Bhatt J, Nevitt SJ. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev. 2017;3(3):002009.
Master V, Roberts GW, Coulthard KP, et al. Efficacy of once-daily tobramycin monotherapy in acute pulmonary exacerbation of cystic fibrosis. Pediatr Pulmonol. 2001;31(5):367-376.
Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J. 2002;19:303-309.
Smyth A, Tan KH, Hyman-Taylor P, et al, TOPIC Study Group. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial. Lancet. 2005;365(9459):573-578.